Sotio Announces Clinical Collaboration With MSD To Evaluate Il-15 Superagonist, SOT101, In Combination With Keytruda In Patients With Solid Tumors; Phase 2 Aurelio-04 Study Will Be Conducted In Us And Selected European Countries And Will Begin In 1H 2022